Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
RSLS was the Nasdaq ticker symbol for ReShape Lifesciences Inc., a physician-led weight loss and metabolic health-solutions company focused on device-based treatments for obesity and metabolic disease. News flow around RSLS has covered both the company e2 80 99s product developments in surgical and medical instruments and its major corporate transactions, including a reverse merger and asset sale.
ReShape Lifesciences frequently announced updates related to its obesity treatment technologies. These included communications about the FDA-approved Lap-Band ae System and Lap-Band ae 2.0 FLEX, the Obalon ae swallowable intragastric balloon technology, and the investigational Diabetes Bloc-Stim Neuromodulation ae (DBSN ae) system for type 2 diabetes and metabolic disorders. The company also issued news about its intellectual property, such as the issuance of a U.S. patent titled e2 80 9cIntragastric Device e2 80 9d covering a swallowable, degradable intragastric balloon system.
In addition to product and IP announcements, RSLS-related news has focused heavily on strategic and financial events. ReShape Lifesciences disclosed a merger agreement with Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, and later reported shareholder approvals, Nasdaq listing approvals, and completion of the merger. Following the closing on August 15, 2025, the public company was renamed Vyome Holdings, Inc. and began trading under the symbol HIND. News items also addressed the sale of substantially all of ReShape e2 80 99s assets to an affiliate of Biorad Medisys, reverse stock split approvals and implementation, cost reduction measures, and Nasdaq compliance updates.
Investors and observers using this RSLS news page can review historical coverage of ReShape Lifesciences e2 80 99 product announcements, patent milestones, corporate governance changes, shareholder meetings, merger progress with Vyome Therapeutics, and the asset sale to Biorad Medisys. This context helps explain how the former RSLS-listed company transitioned into Vyome Holdings, Inc. and why the stock now trades under the HIND symbol on The Nasdaq Capital Market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ReShape Lifesciences (Nasdaq: RSLS) announced it will showcase data on its innovative Diabetes Bloc-Stim Neuromodulation (DBSN) device at the Keystone Symposia on Type 2 Diabetes from May 1-4, 2023, in Palm Springs, CA. The DBSN device aims to improve glycemic control in patients with early-stage diabetes by utilizing sub-diaphragmatic vagus nerve neuromodulation. Study results indicate significant improvements in glycemic control, allowing Fasting Plasma Glucose to decrease from an average of 102 mg/dL to 74 mg/dL. A survey showed that 82% of type 2 diabetes patients interested in lifestyle changes would consider a device like DBSN. Paul Hickey, the CEO, emphasized the market potential of this technology, which could reduce dependence on medications and enhance personalized treatment approaches.
FAQ
What is the current stock price of ReShape Lifesciences (RSLS)?
What is the market cap of ReShape Lifesciences (RSLS)?
